JRJudith G. Regensteiner

Judith G. Regensteiner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Judith G. Regensteiner has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Jane E. B. Reusch

    Division of Endocrinology, Department of Medicine, University of Colorado School of Medicine (UCSOM), Aurora, CO 80045, USA

    4 shared publications
  • Timothy A. Bauer

    Division of Endocrinology, Department of Medicine, University of Colorado Denver, Aurora, CO

    3 shared publications
  • William R. Hiatt

    Department of Medicine, Divisions of Internal Medicine and Cardiology and Internal Medicine and Geriatrics, The University of Colorado Health Sciences Center, Denver, Colorado

    3 shared publications
  • Eugene E. Wolfel

    Division of Cardiology, Department of Medicine, University of Colorado Denver, Aurora, CO

    2 shared publications
  • Susan Smith

    Department of Medicine, Division of Internal Medicine, University of Colorado Health Sciences Center, Denver, CO, USA

    2 shared publications
  • Alan T Hirsch

    Division of Epidemiology and Community Health, University of Minnesota School of Public Health and Vascular Medicine Program, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA

    1 shared publication

Latest Publications

  • Cardiac Dysfunction during Exercise in Uncomplicated Type 2 Diabetes

    by Judith G. Regensteiner, Timothy A. Bauer, Jane E. B. Reusch, Robert A. Quaife, Marcus Y. Chen, Susan C. Smith, Tyler M. Miller, Bertron M. Groves, Eugene E. Wolfel

    Ssociated with impaired cardiac function and hemodynamics in recently diagnosed T2DM, even in the absence of clinically evident cardiovascular complications. Methods: After baseline normal echocardiography screening, 10 premenopausal women with uncomplicated T2DM (average duration of diagnosed T2DM, 3.6 yr) and 10 healthy nondiabetic women of similar age, weight, and activity levels performed a peak cardiopulmonary exercise test while instrumented with an indwelling pulmonary artery catheter for assessing cardiac function. On separate days, technetium-99m sestamibi (cardolite) imaging was performed to assess myocardial perfusion at rest and peak exercise in seven T2DM and seven control patients. Results: Resting measures of cardiac hemodynamics were similar in T2DM and control subjects. Absolute V˙O2peak (mL·min−1) and peak cardiac output (L·min−1) tended to be lower in T2DM than in control subjects but did not reach statistical significance. However, pulmonary capillary wedge pressure (PCWP) rose significantly more during exercise in T2DM than in controls (148% vs 109% increase at peak exercise, P < 0.01). Normalized myocardial perfusion index was lower in persons with diabetes than in controls (11.0 ± 3.5 × e−9 vs 17.5 ± 8.1 × e−9, respectively, P < 0.05) and inversely related to peak exercise PCWP (R = −0.56, P < 0.05). Conclusions: Cardiac hemodynamics during graded exercise are altered in women with recently diagnosed T2DM as demonstrated by the disproportionate increase in PCWP at peak exercise compared with controls subjects. Cardiac abnormalities observed are potentially early signs of subclinical cardiac dysfunction associated with T2DM, which may precede the more greatly impaired cardiac function at rest and with exercise observed in longer established T2DM....


  • Open Access

    The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program

    by Judith G Regensteiner, William R Hiatt, Joseph R Coll, Michael H Criqui, Diane Treat-Jacobson, Mary M McDermott, Alan T Hirsch

    This study tested the hypothesis that patients with PAD have impaired health-related quality of life (HRQoL) to a degree similar to that of patients with other types of cardiovascular disease (other-CVD), and also evaluated the clinical features of PAD associated with impaired HRQoL. This was a cross-sectional study in 350 primary care practice sites nationwide with 6,499 participants. The reference group had no clinical or hemodynamic evidence of PAD or other-CVD; the PAD group had an ankle-brachial index < 0.90 or a prior history of PAD; the other-CVD group had a clinical history of cardiac or cerebral vascular disease (but no PAD), and the combined PAD-other-CVD group included both diagnoses. Individuals were assessed using four HRQoL questionnaires including the Walking Impairment Questionnaire (WIQ), Medical Outcomes Study SF-36 (SF-36), Cantril Ladder of Life and the PAD Quality of Life questionnaire. PAD patients had lower WIQ distance scores than the other-CVD group. Both the PAD and other-CVD groups had significantly lower SF-36 Physical Function scores compared with the reference group. The WIQ revealed that PAD patients were more limited by calf pain, whereas other-CVD patients were more limited by chest pain, shortness of breath and palpitations. In conclusion, in this nationwide study, one of the first to directly compare the HRQoL burden of CVD with that of PAD, the evaluation of PAD in office practice revealed a HRQoL burden as great in magnitude as in patients with other forms of CVD.


  • Established and evolving medical therapies for claudication in patients with peripheral arterial disease

    by Judith G Regensteiner, Kerry J Stewart

    Claudication is a disabling complication of peripheral arterial disease. Therapy aims to minimize the risk of related cardiovascular events and to improve patients' walking ability by limiting the claudication symptoms. Judith Regensteiner and Kerry Stewart present information on the pharmacological and exercise therapy options currently available. Claudication resulting from peripheral arterial disease causes substantial impairment in the ability to carry out normal daily activities. The medical treatments for claudication that are currently available are exercise rehabilitation and one drug, cilostazol. Pentoxifylline, which improves red cell deformability, lowers fibrinogen levels and decreases platelet aggregation, has been used historically, but frequency of use has declined because of limited effectiveness. Exercise rehabilitation, while efficacious, has been underused in the past. This therapy is, however, currently the subject of several large research projects. These studies are investigating mechanisms by which exercise therapy could benefit people with claudication and are also directly comparing it with other therapies. Concurrently, several new drug therapies for claudication are in the process of being evaluated. These research efforts might increase the available armamentarium and thereby help to alleviate the impairments associated with this symptom. The aim of this article is to discuss the current medical treatments being developed for use in patients with claudication resulting from peripheral arterial disease.


  • Open Access

    Rosiglitazone Improves Exercise Capacity in Individuals With Type 2 Diabetes

    by Judith G. Regensteiner, Timothy A. Bauer, Jane E.B. Reusch

    OBJECTIVE—Although exercise is recommended as a cornerstone of treatment for type 2 diabetes, it is often poorly adopted by patients. We have noted that even in the absence of apparent cardiovascular disease, persons with type 2 diabetes have an impaired ability to carry out maximal exercise, and the impairment is correlated with insulin resistance and endothelial dysfunction. We hypothesized that administration of a thiazolidinedione (TZD) agent would improve exercise capacity in type 2 diabetes. RESEARCH DESIGN AND METHODS—Twenty participants with uncomplicated type 2 diabetes were randomly assigned in a double-blind study to receive either 4 mg/day of rosiglitazone or matching placebo after baseline measurements to assess endothelial function (brachial artery diameter by brachial ultrasound), maximal oxygen consumption ([Vdot]o2max), oxygen uptake ([Vdot]o2) kinetics, and insulin sensitivity by hyperinsulinemic-euglycemic clamp. Measurements were reassessed after 4 months of treatment. RESULTS—Participant groups did not differ at baseline in any measure. Rosiglitazone-treated participants (n = 10) had significantly improved [Vdot]o2max (19.8 ± 5.3 ml · kg−1 · min−1 before rosiglitazone vs. 21.2 ± 5.1 ml · kg−1 · min−1 after rosiglitazone, P < 0.01), insulin sensitivity, and endothelial function. A change in [Vdot]o2max correlated with improved insulin sensitivity measured by clamp (r = 0.68, P < 0.05) and with improved brachial artery diameter (r = 0.70, P < 0.05). Placebo-treated participants (n = 10) showed no changes in [Vdot]o2max (19.4 ± 5.2 ml · kg−1 · min−1 before rosiglitazone vs. 18.1 ± 5.3 ml · kg−1 · min−1 after rosiglitazone, NS) or brachial artery diameter. CONCLUSIONS—This is the first known report showing that a TZD improved exercise function in type 2 diabetes. Whether this is due to the observed improvements in insulin sensitivity and/or endothelial function or to another action of the TZD class requires further exploration.


  • Exercise Rehabilitation for the Patient with Intermittent Claudication: A highly Effective yet Underutilized Treatment

    by Judith G. Regensteiner

    Peripheral arterial disease (PAD), when accompanied by claudication, is a disabling disease that affects 12 percent of the population of the United States (US). PAD is associated with increased mortality as well as decreased functional status and quality of life. Smoking cessation and treatment of diabetes are key aspects of risk factor modification for the PAD patient as well as controlling other cardiovascular risk factors. Typically, only the most severely diseased patients with PAD receive surgery for the indication of claudication and other therapeutic options are being sought. Exciting developments are taking place in the area of drug development for instance. The benefits of a supervised walking exercise program have been consistently demonstrated in persons with PAD and therefore, exercise rehabilitation constitutes an important form of therapy for these persons. Unfortunately, in the US, exercise rehabilitation is not always reimbursed which may lessen its utility presently. All therapies which are used to treat claudication should incorporate measures of functional status and quality of life in addition to treadmill walking in order to ascertain the benefit of a given treatment for patients with PAD.


  • Open Access

    Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes

    by Judith G Regensteiner, Shawn Popylisen, Timothy A Bauer, JoAnn Lindenfeld, Edward Gill, Susan Smith, Cheryl K Oliver-Pickett, Jane Eb Reusch, John V Weil

    Endothelial dilator function is impaired in people with type 2 diabetes mellitus (T2DM). Prior research indicates that this can be improved with intravenous administration of ascorbate or L-arginine, but whether these agents have this effect when administered by the clinically practical oral route is unknown. To investigate this question, 10 premenopausal women with T2DM and 10 healthy, premenopausal, non-diabetic women received, in random sequence, a 1-week administration of oral L-arginine (9 g daily) or vitamins E (1800 mg) and C (1000 mg) with an intervening 1-week washout period. Flow-mediated brachial artery dilation (FMD) was measured by ultrasonography and forearm blood flow was measured by plethysmography before and following blood pressure cuff-induced forearm ischemia before and after each week of treatment. At baseline, the women with T2DM had lesser FMD responses (0.028 ± 0.006 cm vs 0.056 ± 0.008 cm, p, 0.05). Post-ischemic forearm hyperemia was reduced at baseline in T2DM compared with controls (16.4 ± 1.8 vs 26.0 ± 1.4 ml 100 ml-1 min-1, p <0.05). Administration of L-arginine caused a 50 ± 12% increase in FMD in T2DM (p < 0.05) and raised post-ischemic forearm blood flow by 29 ± 8% (p < 0.05). No significant changes were seen in controls. Administration of vitamins E and C in women with T2DM produced an increase in the brachial artery diameter response of 79 ± 15% (p < 0.05), but did not significantly increase the hyperemic blood flow response (p = NS). No significant changes in the responses of controls from pre to post vitamin administration were observed. We concluded that administration of two types of oral agents improved measures of endothelial function in people with T2DM.


  • Effect of Cilostazol on Treadmill Walking, Community‐Based Walking Ability, and Health‐Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta‐Analysis of Six Randomized Controlled Trials

    by Judith G. Regensteiner, John E. Ware, Walter J. McCarthy, Peter Zhang, William P. Forbes, Jeffrey Heckman, William R. Hiatt

    OBJECTIVES: To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community‐based walking ability and health‐related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD). DESIGN: Retrospective meta‐analysis of data pooled from six Phase 3, multicenter, double‐blind, placebo‐controlled, parallel‐group, randomized studies. SETTING: Patients were recruited from outpatient ambulatory medical care facilities. PARTICIPANTS: Patients' (n = 1,751) mean age ± standard deviation was 65 ± 9, and they had a history of PAD for 6 months or longer and an ankle brachial index (ABI) of 0.90 or less. INTERVENTION: Cilostazol 50 mg bid or 100 mg bid for 12, 16, or 24 weeks. MEASUREMENTS: ABI; maximal walking distance (MWD); pain‐free walking distance on a graded and constant‐load treadmill; and HQL, measured using the Walking Impairment Questionnaire (WIQ) and the Medical Outcomes Study Short Form‐36 (SF‐36). RESULTS: Maximal treadmill walking distance improved more in both cilostazol groups than in the placebo group (both P < .0001). WIQ and SF‐36 physical summary scores improved significantly more with cilostazol than with placebo (for instance, WIQ distance score, P < .0001 and SF‐36 physical summary score, P < .0001, comparing persons taking cilostazol with controls). Improved MWD correlated with improvements in WIQ (correlation with distance score, r = 0.34, P < .0001) and SF‐36 physical summary scores ( r = 0.29, P < .0001). CONCLUSIONS: Treatment with cilostazol was associated with greater improvements in community‐based walking ability and HQL in patients with intermittent claudication than treatment with placebo. These improvements correlated with increased MWD. This analysis of effects of cilostazol on improving walking ability in persons with claudication is the first cilostazol study focused on community‐based measures of functional status and HQL. Questionnaires assessing walking ability and HQL provide important patient‐based information about clinical outcomes of claudication therapy.


  • Treatment of peripheral arterial disease

    by Judith G. Regensteiner, William R. Hiatt


  • Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus

    by Judith G. Regensteiner, Timothy A. Bauer, Jane E. B. Reusch, Suzanne L. Brandenburg, Jeffrey M. Sippel, Andria M. Vogelsong, Susan Smith, Eugene E. Wolfel, Robert H. Eckel, William R. Hiatt

    Persons with type II diabetes mellitus (DM), even without cardiovascular complications have a decreased maximal oxygen consumption (V˙o2 max) and submaximal oxygen consumption (V˙o2) during graded exercise compared with healthy controls. We evaluated the hypothesis that change in the rate ofV˙o2in response to the onset of constant-load exercise (measured byV˙o2-uptake kinetics) was slowed in persons with type II DM. Ten premenopausal women with uncomplicated type II DM, 10 overweight, nondiabetic women, and 10 lean, nondiabetic women had aV˙o2 maxtest. On two separate occasions, subjects performed 7-min bouts of constant-load bicycle exercise at workloads below and above the lactate threshold to enable measurements of V˙o2kinetics and heart rate kinetics (measuring rate of heart rate rise).V˙o2 maxwas reduced in subjects with type II DM compared with both lean and overweight controls ( P < 0.05). Subjects with type II DM had slowerV˙o2and heart rate kinetics than did controls at constant workloads below the lactate threshold. The data suggest a notable abnormality in the cardiopulmonary response at the onset of exercise in people with type II DM. The findings may reflect impaired cardiac responses to exercise, although an additional defect in skeletal muscle oxygen diffusion or mitochondrial oxygen utilization is also possible.